Stock listing
OTC:HMTXF Hemostemix Inc Stock
US listing (OTC) of Hemostemix Inc · home listing TSXV:HEM
Follow Hemostemix Inc into a list and get an email when it puts out news.
Share price · OTC:HMTXF
$0.027 USD +0.003 (+11.7%)
Close on Nov 17, 2026
- Day range
- $0.027 – $0.027 USDNov 17, 2026
- Volume
- 17,140 sharesNov 17, 2026
- Market cap
- $5.64M USDAt the close on Nov 17, 2026 · price × 211.3M shares outstanding
- 52-week range
- $0.024 – $0.076 USDLowest and highest trades, Nov 18, 2025 – Nov 17, 2026
- Traded on an average day
- $312 USDMedian day 0 shares · 45 days with no trades · last 3 months, Aug 17, 2026 – Nov 17, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:HEM · Home | $0.035 CAD | 0.000 (0.0%) | 1,000 | $0.035 | $0.035 | $0.035 | $0.035 | Close on Nov 20, 2026 |
| OTC:HMTXF | $0.027 USD | +0.003 (+11.7%) | 17,140 | $0.027 | $0.027 | $0.027 | $0.024 | Close on Nov 17, 2026 |
| Frankfurt:2VF0 | €0.012 EUR | -0.003 (-17.2%) | — | €0.012 | €0.012 | €0.012 | €0.015 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 17, 2026 – Nov 17, 2026 · OTC:HMTXF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.027 | +0.003 | +11.7% | $0.027 | $0.027 | $0.027 | 17,140 | |
| $0.024 | -0.011 | -31.7% | $0.031 | $0.031 | $0.024 | 79,000 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 41,000 | |
| $0.035 | -0.001 | -2.0% | $0.035 | $0.036 | $0.035 | 119,100 | |
| $0.036 | -0.001 | -2.5% | $0.036 | $0.036 | $0.036 | 2,000 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | -0.004 | -10.5% | $0.037 | $0.037 | $0.037 | 32,999 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | 0.000 | 0.0% | $0.041 | $0.041 | $0.041 | 0 | |
| $0.041 | +0.001 | +1.5% | $0.041 | $0.041 | $0.041 | 11,000 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | +0.000 | +0.5% | $0.040 | $0.040 | $0.040 | 2,000 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.041 | $0.041 | $0.040 | 24,463 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | -0.003 | -7.8% | $0.042 | $0.042 | $0.040 | 10,500 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 220 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | -0.007 | -13.0% | $0.044 | $0.044 | $0.044 | 800 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 0 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 2,250 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 0 | |
| $0.050 | -0.003 | -6.2% | $0.051 | $0.051 | $0.050 | 59,000 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | -0.001 | -1.3% | $0.053 | $0.053 | $0.053 | 450 | |
| $0.054 | +0.001 | +2.3% | $0.055 | $0.055 | $0.054 | 39,835 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.055 | $0.055 | $0.053 | 10,000 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | 0.000 | 0.0% | $0.053 | $0.053 | $0.053 | 0 | |
| $0.053 | -0.002 | -4.0% | $0.052 | $0.053 | $0.052 | 14,007 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 8,800 | |
| $0.055 | +0.000 | +0.4% | $0.054 | $0.055 | $0.054 | 1,628 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | +0.005 | +10.5% | $0.051 | $0.055 | $0.051 | 30,000 | |
| $0.050 | +0.006 | +13.0% | $0.050 | $0.050 | $0.050 | 20,258 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 |
Splits
1 split · OTC:HMTXF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- OTC:HMTXF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference
Latest deck · Nov 4, 2026
Investor Presentation (2026)
Investor deck · 17 slides
Latest news
Small Cap Growth Virtual Investor Conference Presentations Now Available On Demand
Nov 20, 2026
Issued by another party
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Oct 7, 2026
Closed $0.044 (0.0%) on Oct 7, 2026
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Sep 28, 2026
Closed $0.05 (0.0%) on Sep 28, 2026
Hemostemix Non Brokered Private Placement
Sep 23, 2026
Closed $0.05 (0.0%) on Sep 24, 2026
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Aug 20, 2026
Closed $0.055 (+10.5%) on Aug 20, 2026
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Aug 12, 2026
Closed $0.044 (0.0%) on Aug 12, 2026
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Jul 30, 2026
Closed $0.047 (0.0%) on Jul 31, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Jul 28, 2026
Closed $0.047 (0.0%) on Jul 28, 2026
Hemostemix grants 6,280,000 options
Jul 22, 2026
Closed $0.055 (0.0%) on Jul 23, 2026
Hemostemix Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 217 in all · newest Nov 20, 2026 · oldest 2013
- Decks
- 14 decks · latest Nov 4, 2026
Where Hemostemix Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:HEM · Home listing | TSXV | Canada | CAD |
| OTC:HMTXF · This page | OTC | United States | USD |
| LS Exchange:A2QQGU | LS Exchange | Germany | EUR |
| Cboe Canada:HEM | Cboe Canada | Canada | CAD |
| Frankfurt:2VF0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QQGU | Lang & Schwarz | Germany | EUR |
| Stuttgart:2VF0 | Stuttgart | Germany | EUR |
| Tradegate:2VF0 | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.03M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.69M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Curative Biotechnology Inc · OTC:CUBT | US$5.34M | US$6.55M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Abpro Holdings, Inc. · OTC:ABPO | US$5.31M | US$1.07M | 2.6× | n/a | n/a | n/a | n/a | n/a | -0.79 |
| CNS Pharmaceuticals, Inc. · NASDAQ:CNSP | US$5.25M | −US$11.96M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.74 |
| Soligenix, Inc. · NASDAQ:SNGX | US$5.14M | −US$3.61M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.76 |
| Rakovina Therapeutics Inc · TSXV:RKV | US$5.10M | US$7.20M | n/a | n/a | n/a | n/a | n/a | n/a | -0.43 |
| StimCell Energetics Inc. · OTC:STME | US$5.10M | US$5.09M | n/a | n/a | n/a | n/a | n/a | n/a | 0.99 |
| Longeveron Inc. · NASDAQ:LGVN | US$5.05M | −US$1.78M | n/a | −1.5× | n/a | 1.1× | n/a | 0.1× | 1.55 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Median of the others | US$5.20M | US$3.08M | 0.8× | 14.3× | 0.9× | 0.7× | 0.1× | 0.99 |
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas A. Smeenk | President & CEO. Co-Founder |
| Fraser Henderson | Chief Medical Officer |
| Shaune Harding | Director of Patient Care & Clinical Operations |
Board
| Director | Role |
|---|---|
| Peter Lacey | Chairman of the Board |
| Desirée Cox | Director |
| Loran Swanberg | Director |
| Ronnie Hershman | Director |
Events
- Next results
- Nov 27, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 29, 2023 · After close | −3.9% |
| Q3 2022 | Nov 29, 2022 · After close | +6.7% |
| Q2 2022 | Aug 30, 2022 · Before open | −38.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 17 slides | Nov 4, 2026 |
| Investor Presentation (2026) | Investor deck | 23 slides | 2026 |
| Investor Presentation (2025) | Investor deck | 22 slides | Nov 3, 2025 |
| Investor Presentation (July 2023) | Investor deck | 23 slides | Jul 5, 2023 |
| Investor Presentation (April 2023) | Investor deck | 24 slides | April 2023 |
| Investor Presentation (November 2022) | Investor deck | 22 slides | November 2022 |
| Investor Presentation (March 2022) | Investor deck | 18 slides | Mar 29, 2022 |
| Non-Deal Roadshow (February 2022) | Roadshow | 14 slides | February 2022 |
| Investor Presentation (January 2021) | Investor deck | 22 slides | Jan 25, 2021 |
| Investor Presentation (April 2019) | Investor deck | 20 slides | Apr 1, 2019 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2018) | Investor deck | 21 slides | Jul 26, 2018 |
| Investor Presentation (November 2015) | Investor deck | 21 slides | Nov 12, 2015 |
| Investor Presentation (September 2015) | Investor deck | 21 slides | September 2015 |
| Investor Presentation (July 2015) | Investor deck | 19 slides | July 2015 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Tranche closed: C$380,500 in the latest tranche · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Use of proceeds: ACP-01 manufacturing, clinical-program preparation, regulatory submissions, physician education and general working capital | Oct 7, 2026 | |
| Private placement of units Tranche closed: C$360,000 raised · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated, directly and indirectly, in the Offering Use of proceeds: Sales, marketing, patient acquisition and commercialization; ACP-01 production; Bahamas regulatory fees; working capital | Jun 26, 2026 | |
| Private placement of units Announced: up to C$1M · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company may participate in the private placement, a related party transaction under MI 61-101 Use of proceeds: Sales, marketing, patient acquisition, physician education, commercialization, ACP-01 production, Bahamas regulatory fees and working capital | Jun 17, 2026 | US$712,555 |
| Private placement of common shares Closed: C$480,000 raised · C$0.12 a share Use of proceeds: General working capital, including regulatory, clinical and commercialization work on ACP-01 (VesCell) | Dec 31, 2025 | US$350,212 |
| Private placement of units Closed: C$518,440 raised · C$0.11 a unit · 1 warrant at C$0.15 for 24 months Buyers: Director of the Company (participating in the Offering) Insiders: Certain directors participated directly and indirectly Use of proceeds: General working capital and ongoing operations, including marketing and sales of VesCell | Dec 2, 2025 | |
| Private placement of common shares Closed: C$280,594 raised · C$0.125 a share Insiders: The investor is arm's length and not a Related Party to the Company. Use of proceeds: General working capital, ongoing operating expenses and business development. | Nov 18, 2025 | US$200,467 |
| Therapy Convertible Debenture Tranche closed: US$1.14M raised Use of proceeds: General working capital, corporate overhead and research and development activities | Aug 20, 2025 | |
| Private placement of units Closed: C$2.97M raised · C$0.1 a unit · 1 warrant at C$0.15 for 24 months Buyers: Peter Lacey (subscribed for $1,500,000); Loran Swanberg (subscribed for $100,000); Mr. Lacey (subscribed to 15,000,000 Units; now owns 24,316,937 Common Shares (13.40% non-diluted)) Insiders: Directors Peter Lacey and Loran Swanberg directly and indirectly participated; related party transaction under MI 61-101 Use of proceeds: Repay CD#1 in full at a 50% discount ($1,250,000) and general working capital, including marketing and sales of VesCell | Jul 31, 2025 | US$2.18M |
| Private placement of common shares Closed: C$469,366 raised · C$0.12 a share Insiders: The investor is arm's length to the Company and is not a Related Party Use of proceeds: General working capital, operational expenses and business development | Jul 4, 2025 | US$345,046 |
| Private placement of common shares Closed: US$336,500 raised · C$0.295 a share Buyers: CytoImmune (USD $336,500 for 1,634,466 Common Shares); CytoImmune Therapeutics LLC (1,634,466 Common Shares at CAD $0.295 each) Use of proceeds: General working capital, including business development activities | May 12, 2025 |
All 11 raises
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$2.73M raised · C$0.05 a unit · 1 warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated in the Offering, a related party transaction under MI 61-101 Use of proceeds: Advance stem cell therapeutics platform, initiate sales and process initial ACP batches, pay fees, and general working capital | Dec 3, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 223 | 495 | 1.10K | 2.45K | 1.69K | 0 | 0 | |||
| Gross profit | -223 | -495 | -1.10K | -2.45K | -1.69K | 0 | 0 | |||
| Research and development | 2.49M | 2.97K | 384.9K | 622.7K | 179.9K | 650.0K | 2.35M | 2.26M | 60.3K | 828.6K |
| Selling, general and administrative | 2.56M | 1.89M | 1.33M | 3.50M | 5.98M | 6.81M | 2.34M | 4.16M | 2.75M | 2.31M |
| Operating income | -5.63M | -1.98M | -2.16M | -4.58M | -6.67M | -7.47M | -4.70M | -6.42M | -2.81M | -3.71M |
| Depreciation and amortization | 46 | 100 | 223 | 495 | 1.10K | 2.45K | 1.69K | 1.69K | 745.6K | 38.6K |
| EBITDA | -5.63M | -1.98M | -2.16M | -4.58M | -6.67M | -7.47M | -4.69M | -6.42M | -2.06M | -3.67M |
| Interest expense | 453.2K | 615.2K | 550.1K | 350.3K | 10.5K | 106.0K | 105.0K | 0 | 1.14M | 2.27K |
| Income before tax | -4.71M | -2.62M | -2.50M | -4.75M | -6.54M | -7.77M | -4.87M | -6.18M | -3.51M | -3.79M |
| Income tax | -3 | 486.9K | -255.8K | 106.0K | 105.0K | 6.22K | -60.2K | -10.3K | ||
| Net income | -4.71M | -2.62M | -2.50M | -5.24M | -6.29M | -7.77M | -4.87M | -6.19M | -3.93M | -3.78M |
| Earnings per share, basic | -0.02 | -0.02 | -0.03 | -0.07 | -0.11 | -0.24 | -0.32 | -0.41 | -0.56 | -1.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 682.1K | 705.7K | 155.4K | 135.7K | 219.4K | 258.0K | 24.1K | 1.47M | 3.96M | 34.8K |
| Short-term investments | 59.6K | 0 | 1.25M | |||||||
| Receivables | 25.1K | 138.9K | 342.7K | 2.06M | 75.8K | 191.2K | 89.1K | 90.4K | ||
| Inventory | -343 | -45.5K | -13.3K | -88.2K | -62.0K | -74.4K | ||||
| Current assets | 846.9K | 991.8K | 313.6K | 464.9K | 562.1K | 2.32M | 99.8K | 1.66M | 5.30M | 125.3K |
| Property, plant and equipment | 406 | 2.00K | 4.45K | 101.8K | ||||||
| Goodwill | 1 | 1 | ||||||||
| Total assets | 846.9K | 991.9K | 313.8K | 465.3K | 563.0K | 2.32M | 104.3K | 1.66M | 5.30M | 227.1K |
| Accounts payable | 1.73M | 2.77M | 2.88M | 2.40K | 4.37M | 3.25M | 2.09M | 1.17M | 412.0K | 953.4K |
| Current liabilities | 1.73M | 2.77M | 2.88M | 2.62M | 4.37M | 3.42M | 4.15M | 1.17M | 464.8K | 3.38M |
| Long-term debt | 3.60M | 4.94M | 4.32M | 4.13M | 1.48M | 312.7K | ||||
| Total debt | 4.32M | 4.13M | 1.48M | 175.0K | 2.06M | 1.39M | ||||
| Total liabilities | 5.82M | 8.20M | 7.68M | 7.23M | 5.85M | 3.42M | 4.15M | 1.17M | 464.8K | 3.69M |
| Shareholders' equity | -4.97M | -7.20M | -7.37M | -6.77M | -5.28M | -1.10M | -4.05M | 487.8K | 4.84M | -3.46M |
| Shares outstanding | 195.3M | 140.6M | 82.5M | 70.0M | 57.4M | 32.2M | 15.0M | 14.9M | 6.98M | 3.37M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.53M | -1.90M | -1.50M | -6.10M | -3.48M | -5.98M | -3.40M | -2.69M | -3.21M | -2.69M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | -6.14K | -6.14K | -6.14K | -1.53K |
| Free cash flow | -4.53M | -1.90M | -1.50M | -6.10M | -3.48M | -5.98M | -3.41M | -2.69M | -3.21M | -2.69M |
| Cash from investing | -6.14K | -6.14K | -6.14K | -1.53K | ||||||
| Cash from financing | 4.66M | 2.45M | 1.52M | 6.02M | 3.27M | 6.21M | 1.96M | 201.6K | 7.14M | 2.22M |
| Share buybacks | 5.89M | 76.0K | ||||||||
| Change in cash | -23.6K | 550.3K | 19.7K | -83.7K | -38.5K | 233.9K | -1.45M | -2.49M | 3.92M | -471.7K |
Cap table
Built by 6ix from Hemostemix Inc’s releases · as of Oct 7, 2026
- Common shares
- 219,051,432
- Fully diluted
- 295,732,757
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 219,051,432 | Oct 7, 2026 |
| Warrants | 70,401,325 | Jul 30, 2026 |
| Options and RSUs | 6,280,000 | Jul 22, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.12 · expire about Jul 2028 |
| Warrants · C$0.12 · expire about Jun 2028 |
| Warrants · C$0.15 · expire about Nov 2027 |
| Warrants · C$0.15 · expire about Jul 2027 |
| Warrants · C$0.12 · expire about Nov 2026 |
| Broker warrants · C$0.06 · expiry not stated |
| Broker warrants · C$0.06 · expiry not stated |
| Broker warrants · C$0.06 · expiry not stated |
| Stock options · C$0.06 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 7, 2026 | 219,051,432 |
| Jul 30, 2026 | 211,441,432 |
| Jun 30, 2026 | 204,996,432 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Desiree Cox | Director · Since May 25, 2026 |
| Fraser Henderson | Chief Medical Officer · Since at least Jan 16, 2026 |
| John M. Viglotti | SVP Corporate Services · Sep 18, 2025 – Nov 4, 2026 · Past |
| Loran Swanberg | Director · Since at least Jul 31, 2025 |
| Peter Lacey | Chairman of the Board · Since at least Mar 9, 2026 |
| Ronnie Hershman | Director · Since at least Nov 4, 2026 |
| Shaune Harding | Director of Patient Care & Clinical Operations · Since at least Dec 4, 2025 |
| Thomas Smeenk | President & CEO. Co-Founder · Since at least Oct 7, 2026 |
Log in to ask 6ix AI your own questions about Hemostemix Inc.